A placebo controlled, randomized, double-blind phase II clinical trial to evaluate tolerability, safety and efficacy endpoints after administration of recombinant human insulin-like growth factor-I/recombinant human insulin-like growth factor binding protein-3 (rhIGF-I/rhIGFBP-3) [mecasermin rinfabate] for 24 weeks in adults with myotonic dystrophy type 1

Trial Profile

A placebo controlled, randomized, double-blind phase II clinical trial to evaluate tolerability, safety and efficacy endpoints after administration of recombinant human insulin-like growth factor-I/recombinant human insulin-like growth factor binding protein-3 (rhIGF-I/rhIGFBP-3) [mecasermin rinfabate] for 24 weeks in adults with myotonic dystrophy type 1

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Mecasermin rinfabate (Primary)
  • Indications Muscular dystrophies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Insmed
  • Most Recent Events

    • 21 Jul 2008 Trial now fully enrolled according to Insmed media release.
    • 21 Jul 2008 Status changed from recruiting to in progress according to Insmed media release.
    • 07 May 2008 Investigators have been added, according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top